89.64
2.64 (3.03%)
| Penutupan Terdahulu | 87.00 |
| Jumlah Dagangan | 602,309 |
| Harga / Buku (P/B) | 16.60 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -4,865.98% |
| EPS Cair (TTM) | -3.45 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -17.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 269.12% |
| Nisbah Semasa (MRQ) | 1.25 |
| Aliran Tunai Operasi (OCF TTM) | -152.60 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -87.22 M |
| Pulangan Atas Aset (ROA TTM) | -48.60% |
| Pulangan Atas Ekuiti (ROE TTM) | -196.12% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Abivax SA | Bercampur | Menaik |
AISkor Stockmoo
| Nilai 35% | -4.2 |
| AI Insight info | NA |
| Penilaian Relatif info | NA |
| Kesihatan Kewangan info | -4.2 |
| Masa 35% | 0.3 |
| AI Technical info | NA |
| Osilator Teknikal info | -0.5 |
| Purata Bergerak Teknikal info | 1.5 |
| Wang Pintar 30% | 0.0 |
| Konsensus Penganalisis info | 0.0 |
| Aktiviti Orang Dalam info | NA |
| Persekitaran | ×1.21 |
| Persekitaran Makro info | -3.3 |
| Sektor berbanding Pasaran (6B) | -22.5% |
| Persetujuan Tonggak | ×1.18 |
| Tidak dikira dalam skor | |
| Volatiliti Harga info | 5.0 |
| Skor Akhir | -1.96 |
|
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Institusi | 50.19% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Darwin Global Management, Ltd. | 30 Jun 2026 | 3,621,583 |
| Helikon Investments Ltd | 30 Jun 2026 | 2,787,131 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |